335 related articles for article (PubMed ID: 23777765)
1. HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.
Stevanovic S; van Bergen CA; van Luxemburg-Heijs SA; van der Zouwen B; Jordanova ES; Kruisselbrink AB; van de Meent M; Harskamp JC; Claas FH; Marijt EW; Zwaginga JJ; Halkes CJ; Jedema I; Griffioen M; Falkenburg JH
Blood; 2013 Sep; 122(11):1963-73. PubMed ID: 23777765
[TBL] [Abstract][Full Text] [Related]
2. Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease.
Rutten CE; van Luxemburg-Heijs SA; Halkes CJ; van Bergen CA; Marijt EW; Oudshoorn M; Griffioen M; Falkenburg JH
Biol Blood Marrow Transplant; 2013 Jan; 19(1):40-8. PubMed ID: 22871556
[TBL] [Abstract][Full Text] [Related]
3. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.
van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF
Front Immunol; 2018; 9():3016. PubMed ID: 30619360
[TBL] [Abstract][Full Text] [Related]
4. Mismatched HLA-DRB3 Can Induce a Potent Immune Response After HLA 10/10 Matched Stem Cell Transplantation.
van Balen P; van Luxemburg-Heijs SAP; van de Meent M; van Bergen CAM; Halkes CJM; Jedema I; Falkenburg JHF
Transplantation; 2017 Dec; 101(12):2850-2854. PubMed ID: 28252558
[TBL] [Abstract][Full Text] [Related]
5. HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia.
Rutten CE; van Luxemburg-Heijs SA; Griffioen M; Marijt EW; Jedema I; Heemskerk MH; Posthuma EF; Willemze R; Falkenburg JH
Leukemia; 2008 Jul; 22(7):1387-94. PubMed ID: 18418406
[TBL] [Abstract][Full Text] [Related]
6. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
[TBL] [Abstract][Full Text] [Related]
7. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion.
Koster EAS; von dem Borne PA; van Balen P; van Egmond EHM; Marijt EWA; Veld SAJ; Jedema I; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; de Wreede LC; Halkes CJM
Transplant Cell Ther; 2023 Apr; 29(4):268.e1-268.e10. PubMed ID: 36587743
[TBL] [Abstract][Full Text] [Related]
8. Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA Class I causing severe acute graft-versus-host disease.
Amir AL; Hagedoorn RS; van Luxemburg-Heijs SA; Marijt EW; Kruisselbrink AB; Frederik Falkenburg JH; Heemskerk MH
Biol Blood Marrow Transplant; 2012 Feb; 18(2):210-9. PubMed ID: 22015995
[TBL] [Abstract][Full Text] [Related]
9. The allogeneic HLA-DP-restricted T-cell repertoire provoked by allogeneic dendritic cells contains T cells that show restricted recognition of hematopoietic cells including primary malignant cells.
Laghmouchi A; Hoogstraten C; van Balen P; Falkenburg JHF; Jedema I
Haematologica; 2019 Jan; 104(1):197-206. PubMed ID: 30237261
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation.
Meyer RG; Britten CM; Wehler D; Bender K; Hess G; Konur A; Hartwig UF; Wehler TC; Ullmann AJ; Gentilini C; Uharek L; Huber C; Kolbe K; Herr W
Blood; 2007 Jan; 109(1):374-82. PubMed ID: 16940425
[TBL] [Abstract][Full Text] [Related]
11. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.
Ghobadi A; Milton DR; Gowda L; Rondon G; Chemaly RF; Hamdi A; Alousi A; Afrough A; Oran B; Ciurea S; Kebriaei P; Popat UR; Qazilbash MH; Shpall EJ; Champlin RE; Bashir Q
Curr Res Transl Med; 2019 May; 67(2):51-55. PubMed ID: 30683577
[TBL] [Abstract][Full Text] [Related]
12. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.
Stumpf AN; van der Meijden ED; van Bergen CA; Willemze R; Falkenburg JH; Griffioen M
Blood; 2009 Oct; 114(17):3684-92. PubMed ID: 19706888
[TBL] [Abstract][Full Text] [Related]
13. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors.
Barge RM; Osanto S; Marijt WA; Starrenburg CW; Fibbe WE; Nortier JW; Falkenburg JH; Willemze R
Exp Hematol; 2003 Oct; 31(10):865-72. PubMed ID: 14550801
[TBL] [Abstract][Full Text] [Related]
14. HLA-DPB1 Reactive T Cell Receptors for Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation.
Klobuch S; Hammon K; Vatter-Leising S; Neidlinger E; Zwerger M; Wandel A; Neuber LM; Heilmeier B; Fichtner R; Mirbeth C; Herr W; Thomas S
Cells; 2020 May; 9(5):. PubMed ID: 32443793
[TBL] [Abstract][Full Text] [Related]
15. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.
Matsushita M; Yamazaki R; Ikeda H; Mori T; Sumimoto H; Fujita T; Okamoto S; Ikeda Y; Kawakami Y
Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.
Koster EAS; von dem Borne PA; van Balen P; Marijt EWA; Tjon JML; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; Halkes CJM; de Wreede LC
Front Immunol; 2024; 15():1335341. PubMed ID: 38545096
[TBL] [Abstract][Full Text] [Related]
18. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2020; 11():1804. PubMed ID: 32973756
[TBL] [Abstract][Full Text] [Related]
19. Priming of Allo-HLA-DP-Specific Reactivity from the Naïve T Cell Compartment Is Not Exclusively Mediated by Professional Antigen-Presenting Cells.
Laghmouchi A; Hoogstraten C; Falkenburg JHF; Jedema I
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1257-1265. PubMed ID: 32165326
[TBL] [Abstract][Full Text] [Related]
20. HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.
Herr W; Eichinger Y; Beshay J; Bloetz A; Vatter S; Mirbeth C; Distler E; Hartwig UF; Thomas S
Leukemia; 2017 Feb; 31(2):434-445. PubMed ID: 27479183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
